A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY MHLW’s Economic Affairs Division Honing in on “4th Round” of Distribution Reform; Era of Bundling Won’t Return
August 27, 2013
-
ACADEMIA Osaka City University Slams Lead Investigators of Diovan Trials; They “Knew of His Novartis Affiliation”
August 26, 2013
-
REGULATORY Pharma Industry to Give Opinions at CSIMC Subcommittee in Sept., Stand against Health Ministry’s Plan to Cut Drug Prices
August 26, 2013
-
REGULATORY MHLW Proposes Plan to Downwardly Revise NHI Prices of Combination Drugs and Drugs Obtained as a Result of Optical Resolution of Racemic Bodies
August 23, 2013
-
BUSINESS Patent Cliff Hits Major Global Drug Makers, Weak Yen Weighs on Japan Sales
August 22, 2013
-
BUSINESS Increasing Awareness of Biosimilars to Establish Them as a New Category; Companies Forming Alliances to Build Development and Marketing System
August 21, 2013
-
BUSINESS ASKA to Roll Out Generics of Takeda Product for 1st Time
August 20, 2013
-
BUSINESS Diovan Generics Developed as AGs, “No Comment” on December Listing: Sandoz
August 20, 2013
-
ACADEMIA Health Ministry’s Diovan Committee Should Question Bosses of Ex-Novartis Employee Too, Says Key Member
August 19, 2013
-
BUSINESS Sandoz Gets Approval for Diovan Generics; AGs Likely to Hit Market 6 Months before Rivals
August 16, 2013
-
ACADEMIA British Journal The Lancet Begins Process of Retracting JIKEI Heart Study
August 16, 2013
-
REGULATORY 3 Ex-Officials of MHLW, NHO Affiliated with Novartis in 2010, Govt Says
August 15, 2013
-
REGULATORY PAFSC 2nd Committee to Review GSK’s Combination Asthma Drug on Aug. 26
August 14, 2013
-
REGULATORY EAD Director Visits 5 Hospital HQ to Urge Early Price Settlements, Greeted with Mixed Enthusiasm
August 13, 2013
-
REGULATORY 41,254 ADR Reports Received from Marketing Authorization Holders in FY2012: MHLW
August 13, 2013
-
BUSINESS Payments to Healthcare Professionals by 10 Drug Makers Top 150 Billion Yen
August 13, 2013
-
REGULATORY MHLW Diovan Committee: 3 More Universities Give 1st Probe Updates, SMART Data Rapped “Sloppy”
August 12, 2013
-
BUSINESS AZ’s Exenatide Promotion to Break Free from Weight-Loss Image of GLP-1 Receptor Agonists
August 9, 2013
-
REGULATORY MHLW Taps 12 Experts to Serve on Diovan Study Committee; J-CLEAR’s Kuwajima, JAMS’s Sone on the List
August 9, 2013
-
REGULATORY PMDA to Make Public Adverse Reactions Reported by Patients by Year-End
August 8, 2013
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…